Swiss Medical Cannabis introduces you to the CBD Jungle Juice flower, a flower of excellence and character.

Cultivée en intérieur avec un savoir-faire méticuleux, cette variété premium incarne la fusion parfaite entre beauté naturelle et relaxation apaisante. La luxuriante verdure de la « Jungle Juice » vous transporte dans un monde de bien-être, avec un taux de THC inférieur à <0,3% et une concentration en CBD inférieure à 10%.

 Now available from SMC Laboratories®.

Our CBD-rich Jungle Juice CBD flower genetics are grown indoors in the best conditions to guarantee you a quality organic product free of pesticides, heavy metals and GMOs.

Once finished, we guarantee a curing period of 3 to 8 weeks to allow the terpenes to develop their full potential and the organoleptic qualities to reach their peak, allowing thescent of the flower to transcend all your senses.

Agricultural hemp*(100%)
Cannabidiol (CBD) less than 10% THC
THC less than 0.3%

*Derived from organic agriculture and the Common Catalogue of Varieties of European Agricultural Species.
Guaranteed free of pesticides, fungicides, chemical fertilizers, heavy metals, additives and allergens.

For private use only.
Do not smoke.

Store in a dry place.
Use by date indicated on packaging.

Fleurs Européennes :
Chaque batch de Fleurs de chanvre expédié en Europe fait ainsi l’objet d’une analyse par un laboratoire indépendant en Suisse, puis d’une contre-analyse par un acteur indépendant en Europe.
Ces deux contrôles de sécurité assurent que nos fleurs mise sur le marché respectent scrupuleusement la réglementation Européenne en matière de Taux de THC (<0,3%).
Nous nous assurons également que les fleurs de chanvre proviennent du catalogue Européen Des variétés agricoles autorisées.

Flowers sold in Switzerland:
As required by the regulations of our country, we assure our Swiss customers that the flowers sold by our company are with a THC level lower than 1%.

All these data are the property of SWISS MEDICAL CANNABIS SA. It is protected by the 91/250/EEC and 96/9/EC directives, which grant copyright protection to computer programs and databases respectively. SWISS MEDICAL CANNABIS SA. reserves the right to take legal action against any copy or reproduction of our information.

We also reserve the right to file a claim for damages, in accordance with article L. 331-1-3 of the CPI, which states that "in order to determine the damages, the court shall take into consideration the negative economic consequences, including loss of earnings, suffered by the injured party, the profits made by the infringer and the moral prejudice caused to the owner of these rights as a result of the infringement.